Abstract 838P
Background
Axi-cel, a chimeric antigen receptor T-cell (CAR T) therapy evaluated in ZUMA-1, and epcor, a bispecific antibody evaluated in EPCORE NHL-1, are treatments for R/R LBCL. In the absence of a head-to-head trial, we conducted an unanchored MAIC to estimate relative treatment effects of axi-cel versus epcor in 3L+ R/R LBCL.
Methods
ZUMA-1 patient-level data were matched (using a logistic propensity score model) to baseline characteristics representing pre-specified clinically relevant prognostic factors in EPCORE NHL-1 (N=157): International Prognostic Index score, ECOG performance status, disease stage, response to last therapy, number of prior lines, primary refractoriness, LBCL subtype, and prior autologous stem cell transplant. Outcomes were objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and grade ≥3 cytokine release syndrome (G3+ CRS). Neurotoxicity was not analysed as definitions differed. Relative effects were hazard/odds ratios (HR/OR). Base case analyses included ZUMA-1 pivotal Cohorts 1+2 (C12; N=101). Scenario analyses of OS and CRS added ZUMA-1 safety Cohorts 4+6 (C1246; N=182).
Results
The effective sample size (ESS) for axi-cel was 30 in the base-case (Table). Axi-cel improved PFS (median 12.5 months) versus epcor (median 4.4 months). ORR, DOR and OS results were comparable with point estimates favoring axi-cel. A higher rate of G3+ CRS was associated with axi-cel but the difference was reduced in the scenario analysis.
Table: 838P
MAIC results
Outcome | Weighted axi-cel versus epcoritamab (95% confidence interval) | |
Base case (C12) ESS=30 | Scenario (C1246) ESS=43 | |
ORR OR | 1.55 (0.65−3.69) | N/A |
PFS HR | 0.51 (0.31−0.85) | N/A |
DOR HR | 0.84 (0.46−1.52) | N/A |
OS HR | 0.77 (0.45−1.30) | 0.67 (0.41−1.10) |
G3+ CRS OR | 5.31 (1.21−23.32) | 4.43 (1.10−17.92) |
Conclusions
Our MAIC suggests axi-cel may be more efficacious in terms of PFS versus epcor but with a higher risk of CRS G3+. Of note, median follow-up was short in EPCORE NHL-1 (10.7 months) compared to ZUMA-1 (60 months [C12] and 24 months [C46]) and differences in prior CAR T exposure could not be adjusted for (39% in EPCORE NHL-1 vs 0% in ZUMA-1).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kite, a Gilead Company.
Funding
Kite, a Gilead Company.
Disclosure
O.O. Oluwole: Financial Interests, Institutional, Advisory Role, Scientific advisory role and consultant to Kite Pharma, Allogene, CERo Therapeutics, Novartis, BlueBird Bio, Bristol Myers Squibb, National Cancer Institute, Leukemia and Lymphoma Society: Kite Pharma. M.D. Ray, H. Smith, C.L. Bellasis Spooner, A.R. Patel: Financial Interests, Personal and Institutional, Full or part-time Employment, A stockholder and current employee of Kite, a Gilead company: Kite Pharma. J.M. Chen, K. Chan, I. Zhang, S. Keeping: Financial Interests, Institutional, Full or part-time Employment, PRECISIONheor received consulting fees from Kite, a Gilead Company: PRECISIONheor. F.L. Locke: Financial Interests, Institutional, Advisory Role, Honoraria from Gilead and Pfizer; scientific advisory role and consultant for AbbVie, ADC, Curio Science, Epizyme, Gilead, Janssen, Kite, a Gilead Company, Pfizer, Nektar, Novartis, Syncopation, and TGR therapeutics: Kite Pharma.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18